mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions
P Kaplonek, D Cizmeci, S Fischinger… - Science translational …, 2022 - science.org
The successful development of several coronavirus disease 2019 (COVID-19) vaccines has
substantially reduced morbidity and mortality in regions of the world where the vaccines …
substantially reduced morbidity and mortality in regions of the world where the vaccines …
Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA
To elicit optimal immune responses, messenger RNA vaccines require intracellular delivery
of the mRNA and the careful use of adjuvants. Here we report a multiply adjuvanted mRNA …
of the mRNA and the careful use of adjuvants. Here we report a multiply adjuvanted mRNA …
mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern
P Kaplonek, S Fischinger, D Cizmeci, YC Bartsch… - Immunity, 2022 - cell.com
SARS-CoV-2 mRNA vaccines confer robust protection against COVID-19, but the
emergence of variants has generated concerns regarding the protective efficacy of the …
emergence of variants has generated concerns regarding the protective efficacy of the …
Single-dose HPV vaccine immunity: is there a role for non-neutralizing antibodies?
A single dose of human papillomavirus (HPV) vaccine against HPV infection (prerequisite
for cervical cancer) appears to be as efficacious as two or three doses, despite inducing …
for cervical cancer) appears to be as efficacious as two or three doses, despite inducing …
[HTML][HTML] Current state of, prospects for, and obstacles to mRNA vaccine development
Highlights•mRNA is a key component of mRNA vaccine as the biological blueprint encoding
for proteins.•mRNA strategies comprise preventive vaccinations for therapeutic vaccines …
for proteins.•mRNA strategies comprise preventive vaccinations for therapeutic vaccines …
A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates
R Hunegnaw, AN Honko, L Wang, D Carr… - Science translational …, 2022 - science.org
Marburg virus (MARV) causes a severe hemorrhagic fever disease in primates with mortality
rates in humans of up to 90%. MARV has been identified as a category A bioterrorism agent …
rates in humans of up to 90%. MARV has been identified as a category A bioterrorism agent …
Single dose of a VSV-based vaccine rapidly protects macaques from Marburg virus disease
A Marzi, A Jankeel, AR Menicucci, J Callison… - Frontiers in …, 2021 - frontiersin.org
Marburg virus (MARV) is a member of the filovirus family that causes hemorrhagic disease
with high case fatality rates. MARV is on the priority list of the World Health Organization for …
with high case fatality rates. MARV is on the priority list of the World Health Organization for …
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
Despite the success of COVID-19 vaccines, severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) variants of concern have emerged that can cause breakthrough infections …
2 (SARS-CoV-2) variants of concern have emerged that can cause breakthrough infections …
Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates
Summary The 2013 Ebola epidemic in Central and West Africa heralded the emergence of
wide-spread, highly pathogenic viruses. The successful recombinant vector vaccine against …
wide-spread, highly pathogenic viruses. The successful recombinant vector vaccine against …
A single immunization with a modified vaccinia Ankara vectored vaccine producing Sudan virus-like particles protects from lethal infection
DC Malherbe, A Domi, MJ Hauser, C Atyeo… - npj Vaccines, 2022 - nature.com
A new vectored vaccine MVA-VLP-SUDV was generated against Sudan ebolavirus (SUDV)
combining the advantages of the immunogenicity of a live attenuated vaccine vector …
combining the advantages of the immunogenicity of a live attenuated vaccine vector …